# Kava
*Source: https://go.drugbank.com/drugs/DB01322*

## Overview

### Description

This compound belongs to the class of organic compounds known as dihydropyranones. These are compounds containing a hydrogenated pyran ring which bears a ketone, and contains one double bond.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available

## Chemical Information

**DrugBank ID:** DB01322

**Synonyms:** Kava

**Chemical Formula:** C
14
H
16
O
3

**SMILES:** COC1=CC(=O)OC(C1)\C=C\C1=CCCC=C1

**Weight:** Average: 232.275
Monoisotopic: 232.109944378

**IUPAC Name:** 6-[(1E)-2-(cyclohexa-1,5-dien-1-yl)ethenyl]-4-methoxy-5,6-dihydro-2H-pyran-2-one

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

0

### Phase 0

0

### Phase 1

4

### Phase 2

5

### Phase 3

0

### Phase 4

1

### Generic Name

Kava

### DrugBank Accession Number

DB01322

### Groups

Approved, Investigational, Nutraceutical, Withdrawn

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Kava (DB01322)
×
Close

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Create Account

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as dihydropyranones. These are compounds containing a hydrogenated pyran ring which bears a ketone, and contains one double bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrans
Sub Class
Pyranones and derivatives
Direct Parent
Dihydropyranones
Alternative Parents
Vinylogous esters
/
Enoate esters
/
Lactones
/
Oxacyclic compounds
/
Monocarboxylic acids and derivatives
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
Substituents
Aliphatic heteromonocyclic compound
/
Alpha,beta-unsaturated carboxylic ester
/
Carbonyl group
/
Carboxylic acid derivative
/
Carboxylic acid ester
/
Dihydropyranone
/
Enoate ester
/
Hydrocarbon derivative
/
Lactone
/
Monocarboxylic acid or derivatives
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Pyrans

### Sub Class

Pyranones and derivatives

### Direct Parent

Dihydropyranones

### Alternative Parents

Vinylogous esters
/
Enoate esters
/
Lactones
/
Oxacyclic compounds
/
Monocarboxylic acids and derivatives
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds

### Substituents

Aliphatic heteromonocyclic compound
/
Alpha,beta-unsaturated carboxylic ester
/
Carbonyl group
/
Carboxylic acid derivative
/
Carboxylic acid ester
/
Dihydropyranone
/
Enoate ester
/
Hydrocarbon derivative
/
Lactone
/
Monocarboxylic acid or derivatives

### Molecular Framework

Aliphatic heteromonocyclic compounds

### UNII

3P306S300W

### CAS number

9000-38-8

### InChI Key

OMNGEVNATYFZGG-BQYQJAHWSA-N

### InChI

InChI=1S/C14H16O3/c1-16-13-9-12(17-14(15)10-13)8-7-11-5-3-2-4-6-11/h3,5-8,10,12H,2,4,9H2,1H3/b8-7+

### Synthesis Reference

Klaus-Peter Schwabe, "Kava-kava extract, process for the production thereof and use thereof." U.S. Patent US5296224, issued November, 1963.
US5296224

### General References

Uebelhack R, Franke L, Schewe HJ: Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry. 1998 Sep;31(5):187-92. [
Article
]
Baum SS, Hill R, Rommelspacher H: Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Oct;22(7):1105-20. [
Article
]
Seitz U, Schule A, Gleitz J: [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med. 1997 Dec;63(6):548-9. [
Article
]
Lim ST, Dragull K, Tang CS, Bittenbender HC, Efird JT, Nerurkar PV: Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci. 2007 May;97(1):214-21. Epub 2007 Feb 27. [
Article
]
Sorrentino L, Capasso A, Schmidt M: Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats. Phytomedicine. 2006 Sep;13(8):542-9. Epub 2006 Aug 14. [
Article
]

### External Links

KEGG Compound
C07611
PubChem Compound
5281052
PubChem Substance
46505711
ChemSpider
4444512
RxNav
285228
Drugs.com
Drugs.com Drug Page
Wikipedia
Kava

### KEGG Compound

C07611

### PubChem Compound

5281052

### PubChem Substance

46505711

### ChemSpider

4444512

### RxNav

285228

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Kava

### State

Solid

### Predicted Properties

Property
Value
Source
Water Solubility
0.0632 mg/mL
ALOGPS
logP
2.74
ALOGPS
logP
2.05
Chemaxon
logS
-3.6
ALOGPS
pKa (Strongest Basic)
-4.8
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
2
Chemaxon
Hydrogen Donor Count
0
Chemaxon
Polar Surface Area
35.53 Å
2
Chemaxon
Rotatable Bond Count
3
Chemaxon
Refractivity
70.38 m
3
·mol
-1
Chemaxon
Polarizability
25.68 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
Yes
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9835
Blood Brain Barrier
+
0.7757
Caco-2 permeable
+
0.7784
P-glycoprotein substrate
Substrate
0.5295
P-glycoprotein inhibitor I
Inhibitor
0.7529
P-glycoprotein inhibitor II
Non-inhibitor
0.8643
Renal organic cation transporter
Non-inhibitor
0.6815
CYP450 2C9 substrate
Non-substrate
0.7903
CYP450 2D6 substrate
Non-substrate
0.8869
CYP450 3A4 substrate
Non-substrate
0.5386
CYP450 1A2 substrate
Inhibitor
0.6492
CYP450 2C9 inhibitor
Non-inhibitor
0.9142
CYP450 2D6 inhibitor
Non-inhibitor
0.924
CYP450 2C19 inhibitor
Inhibitor
0.6734
CYP450 3A4 inhibitor
Non-inhibitor
0.8919
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.5086
Ames test
Non AMES toxic
0.7569
Carcinogenicity
Non-carcinogens
0.9371
Biodegradation
Ready biodegradable
0.7719
Rat acute toxicity
1.8786 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.8457
hERG inhibition (predictor II)
Non-inhibitor
0.9466
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0950000000-3f8a7eebc80b33cd9301
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0a4i-0900000000-e7b59a797a95fa6a44aa
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0a4i-0900000000-22fbf6926e257eba9b82
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-3910000000-948eb284d19250268281
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0a6r-7900000000-f47baeea95ece075c3aa
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-00mo-9510000000-ace4ee9abcf2917760a4
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
156.03647
predicted
DeepCCS 1.0 (2019)
[M+H]+
158.43202
predicted
DeepCCS 1.0 (2019)
[M+Na]+
164.45416
predicted
DeepCCS 1.0 (2019)

